Aerpio Pharmaceuticals Inc (ARPO)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

9987 CARVER ROAD CINCINNATI, OH 45242

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for indications in which the Company believes that activation of Tie2 may have therapeutic potential. The Company's lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase ("VE-PTP"). The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema ("DME"). The Company's third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924's exclusive licensor, Gossamer Bio, Inc.. In January 2021, the Company announced that it had initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company's clinical assets and cash resources.

Data as of 2021-07-25 17:32:51 -0400
Market Cap98.278 Million Shares Outstanding47.477 Million Avg 30-day Volume16.066 Million
P/E Ratio0.0 Dividend Yield0.0 EPS0
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-0.08 Enterprise Value
Total Cash Current Debt Gross Profit
BETA-0.34194 52-week High/Low3.32 / 0.9541 Next Earnings Date2021-08-09 Price to Cash FLow (P/CF) -18.0076
Data provided by IEX Cloud
View SEC Filings from ARPO instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 2 0.0% 1 (0.06%) 1 (0.06%) 0.0%
Funds Holding: 43 41 4.88% 17 (1.0%) 17 (0.99%) 0.0%
13F shares: 26.563 Million 19.77 Million 34.36% 23.196 Million 15.558 Million 49.09%
% Ownership 56.1437 41.9635 33.79% 49.0256 33.0241 48.45%
New Positions: 10 12 -16.67% 5 8 -37.5%
Increased Positions 10 10 0.0% 9 3 200.0%
Closed Positions 8 5 60.0% 5 3 66.67%
Reduced Positions 10 9 11.11% 1 4 -75.0%
Total Calls
Total Puts
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ARPO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ARPO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CASTELEIN CALEY

  • Director
295,414 2021-06-30 3

PRELACK STEVEN

  • Director
24,485 2021-06-30 2

DUGEL PRAVIN

  • Director
12,568 2021-06-30 3

DALAL ANUPAM

  • Director
16,959 2021-06-30 3

COHEN CHERYL

  • Director
16,160 2021-06-30 4

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP V LLC

  • 10% Owner
5,193,946 2020-12-08 1

PETERS KEVIN G. SEE REMARKS

  • Officer
0 2020-03-16 0

GARDNER JOSEPH H. PRESIDENT

  • Officer
  • Director
0 2020-03-16 0

MAREK REGINA VICE PRESIDENT OF FINANCE

  • Officer
0 2020-03-16 0

SATTER MUNEER A

  • Director
  • 10% Owner
0 2019-06-18 0

KHUONG CHAU QUANG

  • Director
  • 10% Owner
0 2019-06-18 0

ROGERS MICHAEL W SEE REMARKS

  • Officer
0 2019-05-14 0

HOFFMAN STEPHEN J CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2019-05-14 0

NOVARTIS BIOVENTURES LTD

NOVARTIS AG

  • 10% Owner
No longer subject to file 2019-04-25 0

PAKOLA STEVE CHIEF MEDICAL OFFICER

  • Officer
0 2019-02-15 0

SATTER MUNEER A

SATTER MUNEER A

  • Director
  • 10% Owner
22,172,068 2019-01-03 0

DESAI DHAVAL CHIEF STRATEGY OFFICER

  • Officer
75,342 2018-05-09 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP V LLC

ISALY SAMUEL D

  • Director
  • 10% Owner
3,653,451 2017-03-15 0

WEISS PAUL M

  • Director
1,303,865 2017-03-15 0

MURPHY JAMES B SEE REMARKS

  • Officer
0 2017-03-15 0

KINLEY MATTHEW P SECRETARY, CFO

  • Officer
  • Director
  • 10% Owner
2,000,000 2008-04-01 0

PAPPAJOHN JOHN PRESIDENT

  • Officer
  • Director
  • 10% Owner
2,000,000 2008-04-01 0

VASSILIOU ARGYRIS

  • 10% Owner
1,000,000 2008-04-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

CASTELEIN CALEY - Director

2021-07-02 17:37:29 -0400 2021-06-30 A 7,811 $1.52 a 295,414 direct -2.2857 24.0 59.4286 3 -2.2857 2

PRELACK STEVEN - Director

2021-07-02 17:38:15 -0400 2021-06-30 A 12,334 $1.52 a 24,485 direct -2.2857 24.0 59.4286 3 -2.2857 2

DUGEL PRAVIN - Director

2021-07-02 17:38:03 -0400 2021-06-30 A 6,331 $1.52 a 12,568 direct -2.2857 24.0 59.4286 3 -2.2857 2

COHEN CHERYL - Director

2021-07-02 17:34:09 -0400 2021-06-30 A 8,140 $1.52 a 16,160 direct -2.2857 24.0 59.4286 3 -2.2857 2

DALAL ANUPAM - Director

2021-07-02 17:38:36 -0400 2021-06-30 A 7,400 $1.52 a 16,959 direct -2.2857 24.0 59.4286 3 -2.2857 2

COHEN CHERYL - Director

2021-06-22 17:42:03 -0400 2021-06-17 A 100,000 a 100,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
AERPIO PHARMACEUTICALS INC ARPO 2021-07-28 18:15:03 UTC -3.6268 3.7068 700000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-28 17:45:03 UTC -3.6268 3.7068 700000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-28 17:15:03 UTC -3.6268 3.7068 700000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-28 16:45:03 UTC -3.6268 3.7068 700000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-28 16:15:02 UTC -3.6268 3.7068 700000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-28 15:45:03 UTC -3.6268 3.7068 700000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-28 15:15:03 UTC -3.6268 3.7068 700000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-28 14:45:02 UTC -5.5417 5.6217 700000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-28 14:15:03 UTC -5.5417 5.6217 700000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-28 13:45:02 UTC -5.5417 5.6217 450000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-28 13:15:03 UTC -5.5417 5.6217 450000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-28 12:45:03 UTC -5.5417 5.6217 450000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-27 22:15:03 UTC -5.5417 5.6217 450000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-27 21:45:03 UTC -5.5417 5.6217 450000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-27 21:15:03 UTC -5.5417 5.6217 450000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-27 20:45:03 UTC -5.5417 5.6217 450000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-27 20:15:03 UTC -5.5417 5.6217 450000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-27 19:45:02 UTC -5.5417 5.6217 450000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-27 19:15:02 UTC -5.5417 5.6217 450000
AERPIO PHARMACEUTICALS INC ARPO 2021-07-27 18:45:03 UTC -5.5417 5.6217 450000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ARPO -4800.0 shares, $-6192.0 2021-03-31 N-PORT

Elevate your investments